Remove 2004 Remove Consumption Remove Data Remove Topical
article thumbnail

The End of ‘Just Say No’ Drug Approach is Underway in America

PrestoDoctor

The data comes from a short window of time but does indicate that legalization has little to no impact on youth usage. With cannabis, Being Adept focuses on a range of topics from concentrates and dabs to the significant changes in strain potency over the decades. New Approaches to Drug Education and Prevention. All Hands On Deck.

article thumbnail

Using Cannabis for ALS: Benefits, Research and Best Strains

Greencamp

Based on the currently available scientific data, it is reasonable to think that cannabis might significantly slow the progression of ALS, potentially extending life expectancy and substantially reducing the overall burden of the disease.”. Using Cannabis for Chronic and Neuropathic Pain: The Complete Guide. 4 ). ( 4 ).

Strains 94
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Best strains and terpenes for migraine relief

The Cannigma

Treating migraine pain is one of the instances where inhaled cannabis consumption, such as smoking or vaping , is important for the right effects and speed of delivery. Edibles won’t produce the same experience, but topicals may be able to help, too. Daily cannabis consumption was an effective treatment for 85% of participants.

Terpenes 132
article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

At the same time, the outlook on cannabis research data is largely positive. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). Data collection. One coder then independently coded the entire dataset and entered the data into NVivo v12.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Regarding the warning for specific populations that based on animal data the pharmaceutical may cause fetal harm. There is sufficient data, as indicated in discussion, that inert ingredients within this newly approved CBD pharmaceutical for the US Market have already been proven to cause harm in the unborn fetus, and not the cannabinoid.